|Day's Range||465.10 - 487.00|
|52 Week Range||436.10 - 657.60|
|PE Ratio (TTM)||30.71|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Indian drugmaker IPCA Laboratories Ltd said the U.S. Food and Drug Administration issued it a warning letter highlighting manufacturing quality lapses at three of its Indian factories. The letter concerns the company's Ratlam and SEZ Indore plants in central India, and the Piparia facility in western India, IPCA said in a statement. The plants have already been banned from supplying to the United States after the FDA inspected them in July 2014, January 2015 and March 2015, and first highlighted the lapses.
India has extended price caps to an additional two antibiotics, in the government's latest effort to improve the affordability of medicines. India's National Pharmaceutical Pricing Authority (NPPA) said in a notice that it had put price caps on the 250 mg strength of ciprofloxacin hydrochloride and the 250 mg and 500 mg strengths of cefotaxime. The NPPA also set new retail prices for specific brands of drugs including those for diabetes and hypertension, according to the notice.
India has extended price caps to an additional 39 drugs ranging from commonly used diabetes treatments to antibiotics, in the government's latest effort to improve the affordability of medicines. Wide-ranging price cuts over the past year have hit several drugmakers in India and have been opposed by many in the industry, who say drug prices in the country are already among the lowest in the world. The new drugs join a price control list that covers more than 500 drugs.